Coronavirus India Update: Vaccines ineffective on Covid-19 new variant Omicron?, WHO issues an alert

Publish Date: 27 Nov, 2021 |

Coronavirus India Update: 

At present, there is an atmosphere of concern around the world about the new variant of Coronavirus 'Omicron'. Along with this, there is also a discussion on whether the current Covid-19 vaccine will be effective against this new variant or not. Now Pfizer and BioNtech have issued a statement in this regard. The statement states that it can’t be clearly stated whether the vaccines will prove effective against the new COVID-19 variant 'Omicron'.

However, according to the Sputnik report, Pfizer and BioNTech have promised to develop a new vaccine against the new variant in about 100 days. The World Health Organization (WHO) has announced that it has identified a new strain of coronavirus, B., which was first found in southern Africa and has named this variant 'Omicron', which is a Greek word.

A vaccine to be made in 100 days- Pfizer and BioNtech:

The companies said in the statement, "Pfizer and BioNTech expect to be able to develop and produce a vaccine against the new variants in approximately 100 days, subject to regulatory approval." According to the report by Sputnik, Pfizer and BioNTech said they expect more data on 'Omicron' within the next two weeks.

Pfizer and BioNTech said that it has been seen that this variant is quite different from the earlier ones. The pharmaceutical companies underlined that they began working on adapting their vaccines to new potential variants months ago.

Countries imposing travel restrictions on South Africa:

This new variant of the Covid-19 virus was first found in South Africa, which has raised the concerns of the world. Many countries have imposed travel restrictions on South Africa to avoid contamination of the Omicron variant including America and Canada among others.


Related videos

यह भी पढ़ें

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy.Accept